

PROVECTUS PHARMACEUTICALS INC

Form 8-K

July 02, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 27, 2013

PROVECTUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in charter)

Nevada
(State or other jurisdiction
of incorporation)

0-9410
(Commission
File Number)

90-0031917
(IRS Employer
Identification No.)

7327 Oak Ridge Hwy., Knoxville, Tennessee
37931
(Address of Principal Executive Offices)

(866) 594-5999
(Registrant's Telephone Number, Including Area
Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 5.07. Submission of Matters to a Vote of Security Holders.

(a) Provectus Pharmaceuticals, Inc. (the "Company") held its annual meeting of stockholders on Thursday, June 27, 2013.

(b) At the annual meeting, the Company's stockholders voted on four proposals. A brief description of and tabulation of votes for each proposal are set forth below.

Proposal 1. The Company's stockholders elected the following directors for a term of one year. There were 48,627,741 broker non-votes with respect to the proposal.

Nominee	For	Withheld
H. Craig Dees, Ph.D.	36,981,997	4,113,424
Timothy C. Scott, Ph.D.	37,023,242	4,072,179
Jan E. Koe	37,122,043	3,973,378
Kelly M. McMasters, M.D., Ph.D.	37,251,193	3,844,228
Alfred E. Smith, IV	37,258,568	3,836,853

Proposal 2. The Company's stockholders approved and adopted an amendment to our Restated Articles of Incorporation, as amended, to increase the number of shares of common stock, par value, \$.001 per share, that we are authorized to issue from 200,000,000 to 250,000,000 shares. There were no broker non-votes with respect to the proposal.

For	Against	Abstain
69,012,676	16,016,357	4,694,129

Proposal 3. The Company's stockholders approved the advisory vote on the compensation of the Company's named executive officers. There were 48,627,741 broker non-votes with respect to the proposal.

For	Against	Abstain
25,347,428	13,473,654	2,274,339

Proposal 4. The Company's stockholders ratified the selection of BDO USA, LLP as the Company's independent auditor for 2013. There were no broker non-votes with respect to the proposal.

For	Against	Abstain
85,317,551	2,623,235	1,782,376

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 2, 2013

PROVECTUS PHARMACEUTICALS, INC.

By: /s/ Peter R.
Culpepper
Peter R. Culpepper
Chief Financial Officer and Chief Operating Officer